Start with where the filings aren't: by 2025, comparatively few siRNA patents were about the basic act of silencing a gene. That problem is largely solved. Almost all the new energy is in one place — delivery.
An siRNA drug silences a gene by destroying its messenger RNA. The chemistry of doing that is mature. The bottleneck is geography: a silencing molecule is useless if it can't reach the diseased tissue intact. So the patent competition has become an arms race over targeting.
The clustering is unmistakable. UMass's grant US12365894B2 covers branched lipid conjugates for specific tissue delivery. Suzhou Ribo's US12497622B2 covers nucleic-acid conjugates and compositions. Publication US20250332190A1 targets a specific cardiovascular gene. Three or more independent groups, all filing on targeting — that's a trend.
Why the convergence? Because whoever controls delivery controls the addressable market. The liver was the first organ siRNA could reliably reach, which is why the early drugs treated liver-linked conditions. Cracking delivery to the heart, muscle, or brain opens entirely new disease categories — and that's worth patenting hard.
The standard caveat: a wave of delivery patents measures where the competition is fiercest, not which approach wins or which drug gets approved. Filing density is a map of intent.
By the numbers, the 2025 siRNA story is a delivery arms race. The silencing is commodity science now; the value, and the filings, have moved to the trucks that carry it — and the prize is each new tissue a drug can finally reach.